Clinical trials: Moderate to Severe Glabellar Lines, active
Glabellar Lines
To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
- Trial name
- NCT06205797
- Testing
- HU-045, Xeomin®
- Where
- South Korea
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Huons Biopharma
Moderate to Severe Glabellar Lines
Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines
This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single/repeated injections of Eveotox in the treatment of moderate to severe glabellar lines.
- Trial name
- NCT06937944
- Testing
- Rcombinant botulinum toxin type A for injection（Eveotox), OnabotulinumtoxinA (Botox)
- Where
- 15 sites in China
- Volunteers
- 669 people
- Sponsor
- JHM BioPharma (Tonghua) Co. , Ltd.
Glabellar Lines
Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines
To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines
- Trial name
- NCT07013279
- Testing
- DWP712 inj., Botox® 100 Units
- Where
- South Korea
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Moderate to Severe Glabellar Lines
A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
The purpose of this study is to assess the effectiveness and safety of a single dose of Corabotase (also known as IPN10200) compared to placebo (double-blind phase) and how well and safely repeat doses of Corabotase work over…
- Trial name
- LAURITE 2 (NCT07435428)
- Testing
- Corabotase
- Where
- 60 sites in United States, France and 2 more
- Volunteers
- 1,300 people
- Sponsor
- Ipsen
Glabellar Lines
Study of DWP450 in Japanese Subjects With Glabellar Lines
Study to Evaluate the Efficacy and Safety of DWP450 in Japanese Subjects with Moderate to Severe Glabellar Lines
- Trial name
- NCT07783763
- Testing
- DWP450 20 U, 0.9% Saline Solution 0.5 mL
- Volunteers
- 120 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Moderate to Severe Glabellar Lines
A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
The purpose of this study is to assess the effectiveness and safety of Corabotase (also known as IPN10200) compared to placebo in the improvement of the appearance of moderate to severe glabellar lines in adult participants.
- Trial name
- LAURITE 1 (NCT07427797)
- Testing
- Corabotase
- Where
- 23 sites in United States, Canada
- Volunteers
- 309 people
- Sponsor
- Ipsen
Upper Facial Lines, Glabellar Lines
A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines
The objective of this Phase 2 study is to assess the safety and efficacy of single treatment of trenibotulinumtoxinE and onabotulibumtoxinA combination in adult participants with moderate to severe upper facial lines.
- Trial name
- NCT07871513
- Testing
- TrenibotulinumtoxinE and OnabotulinumtoxinA, OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- AbbVie
Moderate to Severe Glabellar Lines
A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
The purpose of this study is to find out about the effectiveness and safety of a single dose of corabotase (also known as IPN10200) compared to placebo works in participants with moderate to severe glabellar lines.
- Trial name
- LAURITE 3 (NCT07779252)
- Testing
- Corabotase
- Where
- 9 sites in China
- Volunteers
- 160 people
- Sponsor
- Ipsen
Glabellar Lines
To Evaluate HU-045 With Moderate to Severe Glabellar Lines
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
- Trial name
- NCT07870694
- Testing
- HU-045, Xeomin®
- Where
- South Korea
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- Huons Biopharma